UPDATE 2-Novartis to buy radiology drug specialist Mariana for …

May 2, 2024 · Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the …

CouponFollow Extension

$1
OFF

UPDATE 2-Novartis To Buy Radiology Drug Specialist Mariana For …

4 weeks from now

May 2, 2024 · Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the …

yahoo.com

$1.75
OFF

Novartis To Acquire Radiopharmaceutical Firm Mariana Oncology …

4 weeks from now

May 3, 2024 · Novartis on Thursday announced plans to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75 billion. ... with early development of drugs targeted at …

radiologybusiness.com

$1
OFF

Novartis To Buy Radiology Drug Specialist Mariana For $1 Billion

4 weeks from now

May 2, 2024 · Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the …

yahoo.com

$1
OFF

Novartis Extends Its Reach In Radiopharmaceuticals With $1B …

4 weeks from now

May 2, 2024 · Novartis’s two commercialized radiopharmaceuticals are from acquisitions: Lutathera came in 2017 followed by Pluvicto in 2018. The Swiss pharma giant’s purchase of …

medcitynews.com

$1
OFF

Novartis To Buy Radiology Drug Specialist Mariana For $1 Billion

4 weeks from now

By Andrey Sychev and Ludwig Burger (Reuters) - Novartis (LON: 0QLR) agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of …

investing.com

$1.75
OFF

Novartis To Acquire Mariana For Up To $1.75B, Expanding …

4 weeks from now

May 2, 2024 · Novartis has agreed to acquire Mariana Oncology for up to $1.75 billion, the companies said today, in a deal that would further expand the buyer’s radiopharmaceutical …

genengnews.com

$1
OFF

Novartis To Buy Radiology Drug Specialist Mariana For $1 Billion

4 weeks from now

May 2, 2024 · In February, it struck a deal to buy German cancer drug developer MorphoSys for 2.7 billion euros ($2.89 billion). ($1 = 0.9348 euros) (Additional reporting by Paul Arnold,; …

aol.com

$1
OFF

Novartis To Buy Radiology Drug Specialist Mariana For $1 Billion

4 weeks from now

Novartis to buy radiology drug specialist Mariana for $1 billion. ... Matthias Williams. REUTERS • May 2, 2024 (Reuters) - Novartis agreed to acquire U.S. radiopharmaceutical company …

westlaw.com

$1.75
OFF

Novartis Digs Deeper In Radiopharma With $1.75bn Mariana Buy

4 weeks from now

3 days ago · That was followed in 2019 by a $2.1 billion purchase of Endocyte and its prostate cancer RLT Pluvicto (lutetium [lu177] vipivotide tetraxetan), which made sales of almost $1 …

pharmaphorum.com

$1
OFF

Why Selling To Novartis Made Sense For Mariana - BioPharma Dive

4 weeks from now

May 3, 2024 · One of those conversations led to Mariana’s own deal, a $1 billion buyout by Novartis that the companies announced Thursday. According to Read, Mariana saw the …

biopharmadive.com

$1
OFF

Novartis Extends Radiopharma Plans With $1 Billion Acquisition

4 weeks from now

May 2, 2024 · N ovartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition. Novartis …

statnews.com

$1
OFF

Novartis Buys Mariana For $1 Billion | C&EN Global Enterprise

4 weeks from now

May 20, 2024 · Novartis is the latest drug company to buy up a radiopharmaceutical -focused biotech firm with its planned purchase of Mariana Oncology for $1 billion. …

acs.org

$1
OFF

Novartis To Buy Radiology Specialist Mariana Oncology For $1 Billion

4 weeks from now

May 2, 2024 · Novartis has been cutting jobs and costs, and spun off its generic drugs business Sandoz last year, part of a focus on fewer therapeutic areas and geographic markets. In …

marketscreener.com

FAQs about UPDATE 2-Novartis to buy radiology drug specialist Mariana for … Coupon?

Will Novartis buy Mariana oncology?

May 2 (Reuters) - Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday. The deal includes up to $750 million of further payments upon achieving certain milestones, it added. ...

Is Novartis a top player in the radiopharmaceutical space?

Novartis is firming its role as the top player in the radiopharmaceutical space with the acquisition of Mariana Oncology for $1bn upfront, and up to $750m in additional milestone-based payments. Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. ...

What is Mariana & Novartis' strategy for end-to-end radiopharmaceutical R&D?

“Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside,” Simon Read, PhD, Mariana’s founder and CEO, said in a statement. “Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.” ...

What's new at Mariana oncology?

This journey has brought us to a new name: We are now Mariana Oncology Check back here for the latest on Mariana Oncology. Acquisition of Mariana Oncology brings together two companies at the forefront of novel radiopharmaceutical development, with a total potential value of up to $1.75 billion ...

Which pharmaceuticals did Novartis buy?

Novartis’s two commercialized radiopharmaceuticals are from acquisitions: Lutathera came in 2017 followed by Pluvicto in 2018. The Swiss pharma giant’s purchase of Mariana continues a newer streak of radiopharmaceuticals dealmaking by other big pharma layers. ...

How much money will Mariana receive from Novartis?

Under the deal, Mariana will receive $1bn and up to $750m in additional milestone payments from Novartis. Novartis will inherit Mariana’s lead asset MC-339, a radioligand therapy (RLT) designed to target small cell lung cancer. Credit: JHVEPhoto via Shutterstock. ...